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Abstract
Protozoan infections remain a major unsolved medical problem in many parts of our world. A
major obstacle to their treatment is the blatant lack of medication that is affordable, effective, safe
and easy to administer. For some of these diseases, including human sleeping sickness, very few
compounds are available, many of them old and all of them fraught with toxic side effects. We
explore a new concept for developing new-generation antiprotozoan drugs that are based on
phosphodiesterase (PDE) inhibitors. Such inhibitors are already used extensively in human
pharmacology. Given the high degree of structural similarity between the human and the
protozoan PDEs, the vast expertise available in the human field can now be applied to developing
disease-specific PDE inhibitors as new antiprotozoan drugs.
The medical problem
Protozoan diseases have always been faithful companions of mankind and are still
prominently with us today [1-3]. Nevertheless, their effect on human health and wellbeing is
dramatically different depending on the region of the world considered. In the industrialized
societies in temperate climes, a number of protozoan pathogens are common, but rarely
cause serious disease, at least in immunologically competent individuals. Toxoplasmosis,
caused by Toxoplasma gondii, is a widespread infection that rarely causes overt symptoms
in otherwise healthy individuals. This relatively complacent picture can alter dramatically
upon immunosuppression, or upon infection of a naive woman during pregnancy [4]. Here,
the fetus can be seriously affected through transplacental infection, and it runs the additional
risk of contracting a perinatally acquired ocular toxoplasmosis [5]. Trichomonas vaginalis is
the most common nonviral, sexually transmitted disease agent worldwide. Since the
infection is mostly asymptomatic, it often goes untreated and is a frequent cause of
pregnancy-related complications or infertility. In addition, Trichomonas infections
significantly increase the susceptibility of women for infection by HIV [6]. Several intestinal
parasites can lead to unpleasant infections. These are usually self-limiting and rarely have
serious consequences [7,8]. Among them, Giardia lamblia is the undisputed leader, with an
estimated 280 million annual cases worldwide [9]. However, the constantly increasing
number of immunocompromised individuals is cause for concern. While infections of
immunologically competent individuals by intestinal parasites such as G. lamblia or
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Cryptosporidium hominis are usually self-limiting, they are frequently fatal in
immunocompromised patients [1,10-12].
In stark contrast to the situation in industrialized countries, diseases caused by protozoan
parasites constitute serious problems in many parts of the developing world. In terms of
publicity, the clear leader is malaria, a complex of four diseases caused by the four
protozoan species Plasmodium falciparum (the most important and most lethal),
Plasmodium malariae, Plasmodium vivax and Plasmodium ovale. Very recently, yet another
species, Plasmodium knowlesi, previously thought to cause malaria only in monkeys, was
recognized as a fifth human malaria agent [13-15]. Approximately half of the world’s
population currently lives under the risk of malaria infections, corresponding to
approximately 3.3 billion people in 109 countries. Only 35 of these countries (30 in Africa
and five in Asia) contribute 98% of all malaria cases, and 89% of all of these occur in sub-
Saharan Africa. In 2008 alone, an estimated 200 million malaria cases occurred, causing
approximately one million deaths, mostly children below 5 years of age. Despite this high
number of fatalities, the most severe impact of malaria is caused by its transient, but no less
devastating, effects on human health and performance, resulting in an estimated annual loss
of approximately 35 million disease-adjusted life years and US$12 billion in direct losses to
the economies of the afflicted countries [16,17,201]. Despite this devastation, malaria is
only the tip of the iceberg of human suffering.
A broader view shows that, besides malaria, a large group of other protozoan infections also
cause great misery and suffering in vast parts of the world. For many of these, good
(according to modern standards of pharmacology) chemotherapy often does not exist.
Among these other protozoan diseases, amoebiasis is probably the most widespread
(approximately 10% of people have their colon infected). Most of the infections are benign,
with limited clinical manifestations. However, in a small percentage of cases, the amoeba
emigrate from the colon and invade the liver. This leads to the formation of constantly
growing liver abscesses that eventually take a fatal course if not treated in time [18]. While
amoebiasis was traditionally ascribed to a single species, Entamoeba histolytica, it has now
become clear that at least three morphologically indistinguishable species can infect the
colon. Two of them, Entamoeba dispar and Entamoeba moshkovskii, are thought to cause
the self-limiting, colon-restricted disease, while only E. histolytica has the capability of
invasiveness. The quantitative role of these three species in amoebiasis epidemiology
remains to be clarified [19].
Another important group of protozoan pathogens are the kinetoplastida, a vast group of
highly motile unicellular organisms propelled by a single flagellum and characterized by a
particular substructure of the mitochondrion, the kinetoplast. Most members of this order are
pathogens of plants or animals, and several of them are of great medical and/or economical
importance. The genus Phytomonas comprises several economically disastrous parasites of
cash crops such as oil palm, coffee, coconut and tomato [20]. Various members of the genus
Trypanosoma are major disease agents for domestic animals [21-23] and cause great
economic losses in South America, Africa and South-East Asia, resulting from decreased
meat and milk production, reduced indirect benefits, such as hides, manure or traction
power, and the loss of highly priced breeding horses or racing camels.
In addition to these veterinary parasites, three members of the genus Trypanosoma,
Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense and Trypanosoma cruzi,
as well as several members of the genus Leishmania including Leishmania major,
Leishmania donovani or Leishmania amazonensis, cause severe human diseases [24]. The
African trypanosomes T.b. rhodesiense and T.b. gambiense cause human sleeping sickness
in sub-Saharan Africa. They are transmitted by the blood-sucking tsetse fly between human
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hosts or between humans and animal reservoirs, such as domestic or game animals. The
disease may take a protracted course and culminates in the infection of the central nervous
system. It is inexorably fatal if not treated [25]. The South-American trypanosome T. cruzi is
the causative agent of Chagas disease in much of southern and middle America, including
the southern parts of the USA. The parasites are transmitted from animals to humans, or
between humans by bedbugs that contaminate the bite wound with their parasite-containing
feces during the blood meal. This disease is particularly insidious because, after an initial
acute phase with a mortality of approximately 10%, it persists without clinical symptoms for
20 or 30 years. While a proportion of the patients never progress beyond the initial state, a
large proportion finally succumbs to the slow but inexorable destruction of the musculature
of the heart, the intestines and the esophagus [26]. Finally, Leishmania infections can
develop along three different courses:
■ A self-limiting, localized cutaneous infection (cutaneous leishmaniasis) that
eventually heals and leaves a circular scar, usually on the face. This disease
occurs in all of the Middle East, including Afghanistan, as well as Brazil,
Colombia, Peru and Bolivia [27];
■ Visceral leishmaniasis, which leads to gross hypertrophy of liver and spleen and
is mostly fatal. A total of 90% of visceral leishmaniasis cases occur in India
(Bihar), Nepal, Bangladesh, Sudan, Ethiopia and Brazil [28,29];
■ The rare mucocutaneous variant in middle and southern America that eventually
destroys the mucocutaneous regions of the oral and nasal cavities and leads to
death, usually through opportunistic bacterial infections [30].
Chemotherapy
Chemotherapy of protozoan infections has been grossly neglected by modern
pharmacological research. Despite the abundance of protozoan infections and their
debilitating consequences, chemotherapy is still mostly based on unsatisfactory and often
dated drugs. The situation is particularly unsatisfactory for ‘tropical’ protozoan infections.
Giardiasis
For the treatment of uncomplicated giardiasis, numberous compounds are available,
including metronidazole (Flagyl®), tinidazol (Fasigyn®) or nitazoxanide (Alinia®, Daxon®
and Nitax®). Despite this relatively comfortable situation, better chemotherapy is still an
urgent medical need [9,31,32], particularly because a high recurrence rate after treatment
and drug resistance remain major problems [9,33].
Toxoplasmosis
For toxoplasmosis, most infections occur without overt clinical signs. The infection must be
treated in immunocompromised patients. Also, treatment is important if a toxoplasma
infection occurs in a naive woman during pregnancy. Here, the infection constitutes a risk
for the developing fetus. In addition, the newborn may contract perinatal ocular
toxoplasmosis during birth [34]. Early in pregnancy, the macrolide antibiotic spiramycin is
often used to minimize the danger of transplacental infection of the fetus. The standard
medication later on, as well as for the other types of Toxoplasma infections, is antifolates in
combination with folinic acid, although the efficacy of this treatment is still under discussion
[4,35]. Better and more effective chemotherapy against toxoplasmosis is, therefore, high on
the research agenda.
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For malaria, a broad range of compounds from different chemical classes and with different
mechanisms of action are available, and research into new drugs and drug targets is ongoing.
However, the rapid development of drug resistance by malaria parasites remains a persistent
problem [36,37]. The recently reported resistance against the latest antimalarial drug class,
the artemisinins, is particularly concerning [38,39]. Artemisinins are considered to interfere
with a variety of intracellular targets, and thus development of resistance was considered
unlikely. In general, the current situation of drug resistance in malaria is that of an intense
competition between the rate of resistance development by the parasite and the efficacy of
developing new drugs and treatment concepts. The malaria parasites are genetically haploid
during all their stages in the human body. This provides for rapid mutation rates and causes
strong selection for resistance whenever they are exposed to drugs at sublethal doses [40].
While this cannot be completely avoided even with the most careful medical practice, the
problem is compounded by circumstances that are difficult to control, such as insufficient
drug dosing, noncompliance with medication schedules and the abundance of low-quality
counterfeit drugs [41].
Chagas disease
The situation is different, although not more promising, for the diseases caused by
kinetoplastid parasites including Chagas disease (T. cruzi), human sleeping sickness
(Trypanosoma brucei) and the various leishmaniases (Leishmania spp). These protozoa are
diploid and, thus, less prone to acquiring drug resistance. Nevertheless, drug resistance and
drug refractoriness are increasing problems in African sleeping sickness and the
leishmaniases [42-44]. In addition, and in contrast to the situation for malaria, the
armamentarium of available drugs is very limited, and research into developing new
compounds has been slow. For Chagas disease, the nitrofurane nifurtimox (Lampit®) and
the nitroimidazole benznidazole (Rochagan®) are used as standard medication, although
their efficacy is suboptimal and they are fraught with serious side effects [45]. The situation
is further complicated by the fact that their efficacy against the chronic stage of the infection
cannot be evaluated due to the lack of reliable diagnostics of the disease during its latent
phase [26].
Sleeping sickness
For the chemotherapy of human sleeping sickness, there are currently only four or five
compounds available. All of them are old (between 20 and 90 years), and all of them are
fraught with serious side effects. Among them, suramin (Germanin®) and pentamidine
(Pentacarinat®, Pentam®), are only effective in the early stages of infection, that is, before
the parasites have penetrated the CNS. In the late stages of infection, the highly toxic
arsenical melarsoprol (Arsobal®) is used as the standard medication, although the toxicity-
induced fatality rate is between 5 and 10%. Resistance to melarsoprol has increased over the
last one to two decades [46], which is a major cause for concern. In western Africa, the
ornithine decarboxylase inhibitor α-difluoro-methyl-ornithine (eflornithine; Ornidyl®) can
be used, but its usefulness is seriously restricted because of the complex application (four
daily intravenous infusions over 2 h duration each, for a period of 2 to 3 weeks) and the
required logistics. Recently, a nifurtimox–eflornithine combination therapy has been
successfully introduced, which may help alleviate these practical problems [47,48].
Interesting developments of potential new sleeping sickness medication are still in the
experimental stages, including the development of myristoyl-transferase inhibitors [49] or
oxaborole 6-carboxamides [50]. Despite a major setback during clinical trials with one lead
compound, the development of orally available diamidines still carries great hope and
excitement [51,52].
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For the leishmaniases, pentavalent antimonials have remained the standard medication in
recent decades, but drug resistance is becoming an increasing problem in various regions of
the world [53]. Although a number of new compounds, such as miltefosine or amphothericin
B, have been developed over the last few years [54-56], effective, safe and cost-efficient
chemotherapy of the leishmaniases still remains to be developed [29,43].
In summary, the chemotherapy of protozoan infections is still unsatisfactory, despite their
enormous influence on human wellbeing and economic productivity in large parts of the
world. For some of these diseases, including Chagas disease, human sleeping sickness and
the leishmaniases, the development of new and better chemotherapy is an urgent medical
need and a challenge for present-day medicinal chemistry.
The ‘inverted magic bullet’ paradigm
Traditionally, the development of new antiparasitic drugs has followed one of two paths:
■ Chance observations, educated guessing from a medicinal chemistry point-
of-view, or repurposing active compounds from other clinical uses. This
approach has led to the early identification of trivalent arsenicals as
potential anti-trypanosomal drugs, based on initial observations in 1906 by
Robert Koch in the field, and followed up by laboratory experimentation by
Paul Ehrlich [57,58]. More recently, this general approach to drug discovery
was supplemented by numerous in vitro whole-cell screening procedures.
■ With the onset of the molecular age, this concept was complemented by
target-based drug finding strategies. Concerning parasitic protozoa, many of
these approaches were implicitly based on Ehrlich’s seminal ‘magic bullet’
concept [58] based on compounds that find their specific (parasite) target
without causing harm to the surrounding host tissue.
While this concept has proven spectacularly productive (for example, in the development of
antibiotics), it was much less powerful when it came to developing antiprotozoan
compounds. The simple reason is that protozoa are genetically and evolutionarily much
closer to their human hosts than are the bacteria, which makes avoiding collateral damage to
the host by antiparasitic compounds correspondingly more difficult. Nevertheless, numerous
highly parasite-specific potential drug targets have been identified in many protozoan
proteomes [202] whose practical suitability will now have to be evaluated. Unfortunately,
many efforts in developing specific drugs for such targets have been ultimately unsuccessful
because they lacked the required financial and technical support. The latter point has proven
particularly difficult, since industrial partners were often reluctant to explore ‘exotic’
parasite-specific drug targets with which they were not acquainted. This reluctance, plus the
effort required to develop high-throughput screening (HTS) assays and set up dedicated hit-
to-lead chemistry programs for discovering inhibitors for poorly investigated enzymes often
‘broke the camel’s back’ and led to the early termination of many such projects. While some
of these obstacles are now on the way to being overcome, the translation of basic research
on parasite-specific but ‘exotic’ potential drug targets to industry-scale screening for
inhibitors and lead-development programs remains a serious bottleneck.
Hence, the question remains if the high conservation between certain host and parasite
enzymes could be turned from an obstacle to a major boon for drug finding. If such a highly
conserved human enzyme happens to already be used as a drug target, and both enzyme
function and inhibitor development for this enzyme are well explored, and if its parasite
homologue is essential for parasite survival, expertise and technology gained with the
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human enzyme could be applied basically as is to developing parasite-selective inhibitors.
The parasite-target enzyme could be introduced into already established HTS campaigns
without the need to greatly alter standard operating procedures. Once good hits are
identified, the medicinal chemistry is already in place to develop hit scaffolds into
compounds with the required selectivity to discriminate between the host and the parasite
enzymes. This strategy essentially turns the old magic bullet concept upside down: instead
of searching for highly parasite-specific, but often biochemically exotic targets, it focuses on
enzymes that are highly conserved between humans and the parasites. Of particular interest
are human enzymes against which inhibitors are already used as medication for various
clinical conditions. The development of inhibitors for the parasite homologues could then
build on the vast expertise already available.
Cyclic nucleotide-specific phosphodiesterases: a conserved target for
parasite-specific drugs?
The inverted magic bullet concept has recently been explored in depth using the cyclic
nucleotide specific phosphodiesterases (PDEs) as a model class of enzymes. PDEs are
highly specific hydrolases that convert the signaling molecules 5′, 3′-cyclic adenosine- or
guanosine-monophosphate (cAMP or cGMP) into the corresponding 5′-monophosphates (5′-
AMP and 5′-GMP), and thus are central players in cyclic nucleotide signaling. The human
genome codes for 11 PDE families and, due to differential splicing mechanisms, an
estimated total of approximately 100 different PDE polypeptides are synthesized and
function in different human tissues [59]. Despite this great variety, the catalytic domains of
all these PDEs are highly similar, not so much in terms of amino acid sequence (30–40%
amino acid sequence identity) as in terms of their 3D structure (see later discussion). They
all belong to the class 1 PDEs that are identifiable by a characteristic signature sequence
[60]. In the vertebrates, the class 1 PDEs are the only enzymes capable of efficiently
hydrolyzing cyclic nucleotides. In some, but not all unicellular eukaryotes, two further PDEs
can exist in addition to the class 1 enzymes, the class 2 PDEs, for example, in the fungi, and
class 3 PDEs in Dictyostelium [61].
All human PDEs are current or potential drug targets and are being investigated by
numerous research groups based in industry and academia. A number of PDE-inhibitor-
based drugs are already on the market for a variety of clinical conditions. These include the
PDE3 inhibitor cilostazol (Pletal®; Otsuka Pharma; for intermittent claudication), the PDE4
inhibitor roflumilast (Daxas®; Nycomed Pharma; for chronic obstructive pulmonary
disease) or the PDE5 inhibitors sildenafil (Viagra®; Pfizer), tadalafil (Cialis®; Lilly ICOS)
or vardenafil (Levitra®; Bayer) for erectile dysfunction. Despite the very high structural
similarity between the catalytic domains of these and other human PDEs, the clinically used
drugs are highly family-selective. This demonstrates that medicinal chemistry has been able
to develop inhibitors that are highly selective for the catalytic domains of their respective
target PDE, with only minimal effects on the closely related catalytic domains of other
PDEs.
The PDEs of T. brucei & L. major
Interestingly, the genomes of many protozoan parasites including those of Toxoplasma,
Plasmodium or the kinetoplastida T. brucei and L. major contain one or several genes for
class 1 PDEs. The genomes of the kinetoplastida code for four different class 1 PDEs and no
other PDE classes, similar to the situation in the human genome. All kinetoplastid genomes
for which sequence data are currently available contain the same complement of PDE genes
[61] (Figure 1), and the respective PDE polypeptides are highly conserved between the
species [62]. PDEA codes for a high-Km, cAMP-specific PDE [63]. PDEB1 and PDEB2 are
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two tandemly arranged genes that code for two highly similar, cAMP-specific PDEs.
Despite their high similarity, their subcellular localization is quite distinct, with TbrPDEB1
localized predominantly in the flagellum, whereas TbrPDEB2 is mainly located within the
cell body [64-68]. PDEC codes for a dual-substrate PDE that contains a FYVE domain at its
N-terminus [69,70]. Finally, PDED has been identified only as a DNA sequence.
Comparative sequence analysis of their catalytic domains has demonstrated that they are as
closely related to the human PDEs as these are among themselves (Figure 2). For two of
these catalytic domains, TbrPDEB1 of T. brucei [KE ET AL., UNPUBLISHED DATA] and LmjPDEB1 of L.
major (see later discussion), x-ray crystallography has recently demonstrated the extensive
degree of structural conservation between human and parasite PDEs over large evolutionary
distances.
Crystal structures of LmjPDEB1 can serve as templates for inhibitor design Structural
architecture
The catalytic domain of LmjPDEB1 (residues 582–940) showed traceable residues 597–931
in the crystal [71]. The catalytic domain of LmjPDEB1 comprises 16 α-helices but no β-
strands (Figure 3). Human PDE4 was used as a reference structure since this enzyme is the
most thoroughly explored human PDE, and for which the largest number of crystal
structures are available. Two divalent metal ions occupy the bottom of the catalytic pocket.
Zinc and magnesium were used, without verification, in the structure refinement. The zinc
ion coordinates with His-685, His-721, Asp-722, Asp-835 and two bound water molecules.
The magnesium ion coordinates with Asp-722 and five water molecules. The octahedral
configuration of the two divalent metals in LmjPDEB1 is comparable with those in the
human PDEs.
The structure superposition between LmjPDEB1 and human PDEs yielded root-mean-square
deviations of 1.3–2.0 Å for comparable Cα atoms of unliganded human PDE1B [72],
unliganded human PDE2A [73], human PDE3B liganded with 3-isobutyl-1-methylxanthine
(IBMX) [74], PDE4D2-IBMX [75], PDE5A1-IBMX [75], PDE7A1-IBMX [76], PDE9A2-
IBMX [77] and PDE10A2-cAMP [78]. This comparison indicates a similar topological
folding of LmjPDEB1 and the human PDEs.
The superposition revealed that helix H9 of the H-loop (residues 729–754 in LmjPDEB1)
and most residues in the M-loop (residues 858–882) of LmjPDEB1 exhibit significant
positional shifts of as much as 3 Å for their Cα atoms from those of the human PDE families
(Figure 4). This difference is approximately twice the overall root-mean-square deviation
between the structures of LmjPDEB1 and human PDEs and is thus statistically significant.
Since the H- and M-loops are directly involved in interaction with the inhibitors [75,79,80],
their conformational changes appear to have implications on the discovery of parasite-
selective inhibitors.
IBMX binding
3-Isobutyl-1-methylxanthine is a nonselective inhibitor for most human PDE families, but it
only weakly inhibits LmjPDEB1 with an IC50 value of 580 μM. IBMX binds to the active
site of LmjPDEB1 with two characteristic interactions that are conserved in most human
PDEs [80]: the O6 atom of the xanthine ring of IBMX forms a hydrogen bond with Nε2 of
Gln-887 of LmjPDEB1, and the xanthine ring stacks against Phe-890 of LmjPDEB1 (Figure
4). The binding of IBMX in the LmjPDEB1 structure is similar to that observed in the
human PDE-IBMX complexes, although the orientation and position of IBMX show
significant differences [78]. These differences may be understandable because the active site
pockets of PDEs are much larger than the volume of IBMX.
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A potential parasite pocket for inhibitor binding
The structural study [71] identified a subpocket in LmjPDEB1, which neighbors the active
site of human PDEs and is close to the binding of the cyclopentyl ring of rolipram in human
PDE4 (Figure 5). This pocket is made up of residues from the M-loop and helix H14,
including Thr-854, Tyr-858, Met-874, Asn-881, Leu-883 and Gly-886 in LmjPDEB1. Two
residues, Met-874 and Gly-886 of LmjPDEB1 are located at the entry of the subpocket and
appear to serve as gate-keeping residues to isolate the subpocket from the active site. In
most human PDE families, the large size of these entry residues isolates the subpocket from
the active site [71]. In the LmjPDEB1 structure, a separation of 7.5 Å between the Cα atoms
of Met-874 and Gly-886 leaves the subpocket wide open and fully accessible. The
corresponding residue Gly-886 is conserved in most other parasite PDEs, except TcrPDEC
and TbrPDEC where it is replaced by serine (Figure 5). However, the residues
corresponding to Met-874 are glycine in both PDECs, thus still leaving the access to the
subpocket open.
Thr-854 and Tyr-858 of helix H14 and Leu-883 and Gly-886 of helix H15 form two walls of
the pocket, while the fragment around Asn-881 of the M-loop constitutes the third side of
the pocket (Figure 5a). Interestingly, the bottom of the subpocket is open to the molecular
surface of LmjPDEB1. Thus, the pocket looks more like an open channel in LmjPDEB1. It
has a size capable of accommodating a five-membered ring and shows mixed hydrophilic
and hydrophobic characteristics. This subpocket shows variation in size and shape in
different parasite PDEs, and we believe that it might be useful for the development of
parasite-selective inhibitors.
The experimental demonstration of the extensive structural conservation between the
catalytic domains of human PDEs and those of T. brucei and L. major sets the stage for
exploiting this extensive similarity by handling parasite PDEs just like yet another human
PDE when it comes to setting up HTS and hit-to-lead development programs, without major
adjustments to standard procedures required.
TbrPDEB1 & TbrPDEB2 of T. brucei are potential drug targets: genetic validation
Early observations had indicated that TbrPDEB1 and TbrPDEB2 might be essential
enzymes for bloodstream form T. brucei [68]. This was confirmed by the use of an inducible
RNA interference (RNAi) system [65]. A tetracycline-inducible RNAi construct (Figure
6a) directed simultaneously against the TbrPDEB1 and TbrPDEB2 was integrated into the
genome of bloodstream form T. brucei that expressed a bacterial tetracycline repressor.
Tetracycline has no effect on wild-type trypanosomes, but it specifically interacts with the
bacterial tetracycline repressor expressed by the genetically altered trypanosome strain. In
the absence of tetracycline, the tetracycline-repressor binds tightly to its operator DNA,
preventing the expression of the double-stranded interfering RNA. The trypanosomes are
perfectly viable and cause virulent infections in mice (Figure 6B). However, if the animals
receive tetracycline in the drinking water for two days before the infection, or during an
ongoing infection, the tetracycline-liganded repressor dissociates from the operator DNA,
double-stranded interfering RNA is transcribed, RNAi is induced and the mRNAs of
TbrPDEB1 and TbrPDEB2 are rapidly degraded. As a result, trypanosomal PDE activity is
strongly diminished, and the intracellular cAMP levels in the trypanosomes rise
dramatically, leading to cell lysis. The parasites are rapidly and permanently eliminated
from the infected animals (Figure 6B) [65].
Pharmacological validation of parasite PDEs as drug targets
Trypanosoma cruzi—The T. cruzi genome contains several PDEs (see earlier
discussion). From these, only TcrPDEC has been validated as a therapeutic target [76]. The
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enzyme has been described by Kunz et al. as an unusual dual-substrate PDE [64]. It is able
to hydrolyze cAMP as well as cGMP, although the biological significance of the latter
activity is unclear.
King-Keller et al. synthesized two classes of compounds and screened their inhibitory
activity against TcrPDEC and human PDE4D2 [81]. In the catechol diether group, the most
interesting inhibitors were found in the series with bulky substituents in the 4-position of the
benzene ring; as expected, this chemical class showed decreased activity against HsPDE4.
Figure 7 presents two of the most interesting compounds from this study in terms of potency
and selectivity.
With both series, a good correlation was found between inhibition of TcrPDEC activity and
amastigote growth inhibition in a myoblast assay; inhibiting this enzyme was found to
influence the parasite’s osmoregulation. Selected compounds were further validated by
showing their effect on increasing the intracellular concentration of cAMP in amastigotes.
Leishmania species—A preliminary target validation of the cAMP signaling pathway in
L. major was obtained by inhibiting promastigote proliferation and infection of macrophages
by high concentrations of a PDE inhibitor (dipyridamole) or by 8-CPT-cAMP [82].
However, because of the high concentrations used and the minimal effects observed, the
evidence for this validation is not entirely conclusive.
A series of commercially available PDE inhibitors was tested against the LmjPDEBs [83].
Only dipyridamole, trequinsin and etazolate caused some inhibition with IC50 values in the
range of 10 to 100 μM. The three inhibitors also inhibited the proliferation of L. major
promastigotes and Leishmania infantum amastigotes in culture, all with IC50 values in the
30–100 μM range. Despite the high inhibitor concentrations required in these experiments,
the results clearly suggest the validity of the Leishmania PDEBs as therapeutic targets, as
was found for T. brucei ([65]; see earlier discussion).
For LmjPDEB1, an IC50 value of 580 μM for the nonselective PDE inhibitor IBMX was
reported ([71]; see earlier discussion). A number of other compounds inhibited the enzyme
>50% at 20 μM, including NVP (a specific inhibitor of human PDE4), dipyridamole and the
flavonoids luteolin and quercetin (Figure 8 & table 1 [T. brucei]).
Plasmodium species—P. falciparum is the only protozoan pathogen apart from T.
brucei and L. major for which the PDEs are at least marginally explored. Its genome
encodes four class 1 PDEs [61,84,85]. Yuasa et al. [86] and Wentzinger et al. [84] described
PfPDEα as a cGMP-selective PDE. While the deletion of the gene for PfPDEα has no
observable effect on the proliferation of P. falciparum in culture [84], deletion of PfPDEβ
disrupts gametocytogenesis [87], and deletion of the PfPDEδ homologue in the mouse
malaria agent P. berghei interferes with gliding motility, ookinete morphology and parasite
transmission [88]. These observations indicate that, in analogy to the situation seen with T.
brucei, inhibition of plasmodial PDEs might well kill the parasite and, through the
disruption of normal gametocytogenesis via PfPDEβ inhibition, also interrupt the
transmission cycle.
Several known PDE inhibitors were tested against PfPDEα, and zaprinast, a known selective
inhibitor of human PDE5 turned out to be the most potent, with an IC50 value of 3.8 μM. In
contrast, the much more potent (against human PDE5) inhibitor sildenafil showed much
lower activity against PfPDEα (IC50 = 56 μM).
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This difference between sildenafil and zaprinast already shows the considerable differences
in the structure-activity relationship between PfPDEα and HsPDE5. This observation seems
to indicate that selective optimization of the PfPDEα inhibiting activity should be possible in
this class of compounds. Target validation of PfPDEα is further supported by the
observation that zaprinast (EC50 = 35 μM; [86]), 8-Br-cGMP (EC50 = 6.25-12.5 μM) and 8-
Br-cAMP (EC50 = 3.13–6.25 μM [101]) inhibit the growth of a plasmodium strain (P.
falciparum Honduras-1) in vitro.
In a patent application from the Institute Pasteur and the University of Lille (France) [102], a
series of β-carbolines were described with potent activity against different P. falciparum
strains in an in vitro proliferation assay. This class of compounds comprises analogues of the
potent and selective PDE5 inhibitor, tadalafil (Cialis®). However tempting it may be to
ascribe the effect of these compounds to PDE inhibition, no proof for this mechanism has
been given, such as a correlation between the effect on Plasmodium proliferation and
changes in intracellular cAMP or cGMP. Compound 70c in this study is an example that
showed approximate equipotency against three different strains of P. falciparum in vitro
(IC50 values: GHA = 0.2 μg/ml; 3D7 = 0.13 μg/ml; K1 = 0.15 μg/ml). Interestingly, some of
the compounds from this patent application were also active in vitro against T.b.
rhodesiense, with compound 28 being the most active with an IC50 value of 0.1 μg/ml.
Trypanosoma brucei—Besides the genetic validation of TbrPDEB1 and TbrPDEB2 as
drug targets in T. brucei (see earlier discussion), some preliminary pharmacological
validation has been performed. Several known PDE inhibitors have been shown to inhibit
both cell proliferation and the TbrPDEB enzymes (IBMX, sildenafil, dipyridamole,
etazolate, ethaverine and trequinsin), although with low potency [68,89]. These results, as
well as the availability of x-ray crystallographic structures for at least two catalytic domains
of kineto–plastid PDEs has sparked activities towards exploring PDE inhibitors as potential
new trypanocidal drugs.
X-ray crystallography data (see earlier discussion) have demonstrated the high degree of
structural conservation between the catalytic domains of human and parasite PDEs. On the
other hand, they have shown the presence of a pocket that is connected to the substrate-
binding pocket, but can only be accessed from there in the parasite PDEs, but not in the
human PDEs. The structural comparison between LmjPDEB1 and human PDE4D suggested
that the scaffold of human PDE inhibitors might be useful for the development of parasite-
selective inhibitors. A model docking shows that the scaffold of the catechol part of rolipram
is seemingly a good starting model (Figure 9a). In an attempt to improve parasite-versus-
host specificity, a long and flexible arm was designed to extend the catechol of the inhibitor
towards the P-pocket. This strategy provided encouraging results. The compound
synthesized in Ke’s laboratory, University of North Carolina at Chapel Hill (USA), showed
an IC50 value of 3.1 μM for the catalytic domain of LmjPDEB1 and 4.6 μM for TbrPDEB1.
Further optimization is in progress. The available crystallographic data will now form the
groundwork for further medicinal chemistry.
The biological validation of T. brucei PDEs as drug targets has been followed up by HTS of
Nycomed Pharma’s proprietary library of 400,000 compounds. Hit-to-lead development of
scaffolds recovered in the screen, as well as of other leads, is now in progress. In addition,
new exploration of chemical space by fragment-based screening is also under way within the
framework of the TI Pharma T4–302 consortium [203].
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The inverted silver bullet concept postulates that suitable parasite-specific drug targets need
not necessarily be highly parasite-specific enzymes or other components of parasite-specific
metabolic pathways. Quite on the contrary, many occasions it might be preferable to target a
parasite enzyme with highly conserved homologues in the human host. If this conserved
human target has already been extensively explored and exploited as a drug target for other
clinical conditions, and specific inhibitors for the human target have been developed, then
the established technology can be applied without major modifications to developing
compounds that inhibit the closely related parasite homologue. Issues of host-versus-parasite
specificity can be confidently taken care of by medicinal chemistry. This approach will
allow mustering the vast expertise and technology of the pharmaceutical industry to address
parasitic diseases, without the need to retool, rethink or reinvent the entire drug screening
and development process.
The PDEs of T. brucei and L. major are suitable targets to explore this concept. They are as
conserved with respect to their human homologues as these eleven human PDE families are
among themselves. Nevertheless, in human pharmacology, highly selective PDE inhibitors
have been developed that potently inhibit one PDE family with minimal crosstalk to PDEs
of others. Given the extensive similarity between human and trypanosomal PDEs, a similar
degree of specificity should also be obtainable for inhibitors of the parasite PDEs.
X-ray crystallography of the catalytic domains of LmjPDEB1 has shown that there are
sufficient differences in the detailed structures of human and Leishmania PDEs to leave
room for chemical improvement of potency and specificity of lead compounds. The
availability of structural data will now considerably speed up this chemical development.
For T. brucei, experimental data have demonstrated that TbrPDEB1 and TbrPDEB2 are
essential enzymes, and that their inactivation by either pharmacological means or by RNAi
leads to rapid cell death in vitro, and to a complete halt of ongoing infections in a mouse
model. Similarly, experimental evidence from the human malaria parasite P. falciparum and
the mouse parasite Plasmodium berghei strongly indicate that interfering with these
parasites’ PDEs may also interrupt the infection. Similar evidence for other protozoan
parasites is still lacking, but the experimental tools are available to follow suit.
The remaining problems with developing PDE inhibitors into antiparasite drugs should not
be underestimated. Besides establishing that PDEs are, in fact, valid drug targets, the
potential interaction of antiparasite PDE inhibitors with human PDEs has to be worked out
for every single case, and the side effects of such inhibitions due to inhibitor crosstalk to
human PDEs remains to be assessed. Nevertheless, the history of developing inhibitors
against individual human PDEs has amply demonstrated that exquisite specificity for a
given human PDE can be obtained, with a negligible effect of an inhibitor of one PDE to
any of the other ten human isoenzymes. However, tailoring an inhibitor for optimal potency
and specificity inevitably makes it more prone for inducing drug resistance by spontaneous,
single-point mutations of the PDE. This is not a problem in all current applications of PDE
inhibitors, such as chronic obstructive pulmonary disease (PDE4 inhibitors) or erectile
dysfunction (PDE 5 inhibitors). In contrast, drug resistance certainly will occur once PDE
inhibitors are used for treating protozoal infections. However, this problem is not specific
for PDE inhibitors, as the long and frustrating experience with drug-resistant parasites amply
documents. Drug resistance will have to be approached by means other than medicinal
chemistry, including the exclusive use of combination drugs, strict enforcement of drug
quality standards also in retail outlets, and a judicious use of the available drugs.
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The generic approach outlined in this study targets parasite enzymes that are highly
conserved homologues of human enzymes that are already extensively studied as drug
targets for a variety of clinical conditions. This strategy offers the unique advantage that
well-established developmental pipelines and standard procedures can also be applied to
develop new anti-parasitic drugs. This repurposing will considerably lower the required
financial and intellectual investments that any company will have to risk when considering
the development of antiparasitic drugs. While this alone might already make such an
undertaking considerably more attractive, an increasing number of public–private and
product-development partnerships [90,201,203-206] serve to facilitate all aspects of drug
development and the cooperation and communication between industry and academia. In
addition, a number of creative financial and regulatory schemes have been developed over
the years to facilitate and accelerate (and ultimately reward) the development of urgently
required drugs against neglected diseases [91,92].
Despite the inevitable remaining obstacles, the case of the PDEs in trypanosomes and
Leishmania has demonstrated the viability of the inverted silver bullet concept. In view of
the fact that the genomes of humans and their protozoan parasites contain a fair number of
highly conserved enzymes, which are well studied drug targets in the human, this approach
might hasten the development of urgently needed new antiparasitic drugs. Hopefully, this
eventually might lead to what Paul Ehrlich envisioned in his 1908 Nobel lecture, namely
that “…It is really possible in every animal species and with every kind of trypanosome
infection to achieve a complete cure with one injection, a result which corresponds to what I
call therapia sterilisans magna” [207].
Future perspective
Over the next decade or so, chemotherapy of protozoal diseases will gain importance for
several reasons:
■ The global exchange of people and disease vectors, in combination with the
projected global warming trends will establish new habitats for protozoal
parasites in areas where they are currently absent or insignificant;
■ For some protozoa, including malaria, the projections indicate an increase in
prevalence, while for others, such as Trichomonas, their significance as a public
health problem is only becoming visible now;
■ The long-term economic development of many major countries will enable them
to allocate more funds to public health problems, including the treatment and
prevention of parasitic diseases;
■ The increasing scientific competence and political influence of many endemic
countries will gradually shift the global research agenda towards addressing
problems that are of major concern to them. These will prominently include the
control, prevention and chemotherapy of infectious diseases.
On the other hand, due to the genetic flexibility of protozoal parasites, the development of
antiprotozoal drug will never be over. Rather, we are locked in an endless race between the
competence and creativity of drug developers and the genetic flexibility and evolutionary
pressure of protozoal parasites. Thus, the quest for new drug targets and new drug scaffolds
will remain a continuous effort.
The field might strongly benefit from newer technical developments, such as the current
deep-sequencing revolution. Eventually, such techniques might permit a much more precise
definition of the genotype of a parasite strain in a given locality or even a given patient,
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hopefully allowing a much more effective selection and dosing of drugs. This would also go
a long way towards reducing the development of drug resistance.
Hopefully, in the long term we might finally learn and, importantly, also apply the lessons
learned of how to prevent parasite infections or reduce vector levels in the first place. A
salient example are the intestinal parasites that could, at least in theory, be completely
eliminated as human-disease agents simply by providing clean drinking water, with no need
of expensive medication or vaccination. Here, the lesson is clear for all to see, and the great
William Trager of Rockefeller University (USA) formulated it so well in 1986 by stating
that “good plumbing has done more for good health than has good medicine”. This is a
timely reminder that we should not too narrowly focus our efforts on pharmacological
solutions, but always remain open to the fact that combating protozoal pathogens is a
multidimensional task where single or simple solutions are bound to fail.
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■ Protozoan parasites remain a huge, unsolved problem in large parts of our
world. Much effort is currently devoted to controlling transmission (e.g.,
through reduction of the relevant insect vectors or improvement of drinking
water quality) or to the development of vaccines. Nevertheless,
chemotherapy remains an important pillar of disease control.
■ Despite the significance of protozoan infections, chemotherapy of these
diseases has not kept pace with modern medicinal chemistry. For most of
these diseases, only unsatisfactory drugs are available.
■ The development of such parasite-specific drugs has been hampered by the
lack of economic incentives: most of the target population cannot afford
expensive medication. As a consequence, such development projects
invariably carry a huge financial risk, and pharmaceutical companies have
been reluctant to initiate drug-development projects against organisms and
target proteins with which they have had no previous experience.
■ We propose a novel approach based on selecting, as potential drug targets,
enzymes that are strongly conserved between the human host and the
parasite. If such a human enzyme is already explored as a drug target, and if
the corresponding parasite enzyme is essential for survival of the parasite,
available expertise and technology can be applied to develop inhibitors that
are fatal for the parasite. This will greatly facilitate the development of
parasite-specific drugs and, thus, will considerably diminish the financial risk
of such projects.
■ The concept is exemplified here by using cyclic nucleotide-specific
phosphodiesterases (PDEs) as an example. Crystallographic analysis has
demonstrated that these enzymes are highly conserved between humans and
the parasites Trypanosoma brucei or Leishmania major.
■ Biological experiments in vitro and in vivo have demonstrated that such
PDEs are essential for parasite survival and for maintaining an infection.
■ High-throughput screening of a proprietary compound library (Nycomed
Pharma) with recombinant PDE from T. brucei using the company’s standard
operating procedures has revealed a number of highly potent compounds.
■ Crystallographic analysis of the parasite PDEs has provided information on
subtle structural differences between the human and the parasite PDEs that
can now be exploited to synthesize optimized lead compounds.
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Kinetoplastida: Systematic order of flagellated, unicellular eukaryotes. Most members
of this order are parasites of multicellular organisms, and several are medically and
economically important disease agents of humans, their domestic animals and their cash
crop. The medically important species are transmitted to humans via insect vectors,
including the tsetse fly (Glossina ssp; Trypanosoma brucei), the sandfly (Phlebotomus
ssp or Lutzomya ssp and the various Leishmania) or bedbugs (e.g., Rhodnius prolixus and
Trypanosoma cruzi).
Sleeping sickness: Inexorably fatal infection of the central nervous system caused by the
kinetoplastid protozoa, Trypanosoma brucei gambiense and Trypanosoma brucei
rhodesiense. The disease is endemic in 38 countries of Sub-Saharan Africa, with an
estimated incidence of approximately 50,000 cases annually. It is a typical neglected
disease that affects the inaccessible, poor rural areas of the countries. Together with the
infections of domestic animals caused by the same and related trypanosomes, sleeping
sickness constitutes a major burden on the afflicted populations and a major impediment
to the economic development of these areas.
Leishmaniases: Complex of several diseases that are all caused by closely related
kinetoplastid protozoa, the Leishmania ssp. The protozoa are transmitted by blood-
sucking sandflies. Depending on the clinical course and the disease agent, three major
disease forms are distinguished: cutaneous leishmaniasis (usually self-healing, but
leaving ugly scars), visceral leishmaniasis (frequently fatal) and mucocutaneous
leishmaniasis (frequently fatal).
Protozoa: Diverse group of single-cell eukaryotic organisms, including many pathogens.
In contrast to bacteria, the protozoa are genetically and biochemically much more closely
related to higher organisms, including mammals. This fact traditionally made the
development of selective chemotherapy much more difficult.
RNA interference: Molecular technique that allows the elimination of a specific target
mRNA from a living cell. The technique allows the quick exploration of whether a given
protein is essential for the target cell. Interfering RNA can be synthesized chemically and
introduced into the target cells from outside (e.g., via electroporation), or it can be
genetically encoded by a DNA construct that is stably integrated into the target cell
genome. The latter mode allows selective induction of RNA interference by placing its
expression under the control of an inducible repressor.
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Figure 1. Schematic representation of phosphodiesterases A–D encoded by kinetoplastid
genomes
Darker boxes: class 1 catalytic domains; lighter boxes: GAF domains; checkered box:
FYVE domain. Size in amino acids of each enzyme (of T. brucei) is indicated in
parentheses. Gene identification numbers [208] are given underneath each scheme.
Lbr: Leishmania braziliensis; Lin: Leishmania infantum; Lmj: Leishmania major;
Tb: Trypanosoma brucei; Tc: Trypanosoma cruzi.
Seebeck et al. Page 21













Figure 2. Unrooted tree of catalytic domains of the phosphodiesterases of human and protozoan
origin
The following sequences were used for ana lysis: HsPDE1A, accession number P54750;
HsPDE2A, O00408; HsPDE3A, Q14432; HsPDE4B, Q07343; HsPDE5A, O76074;
HsPDE6B, P35913; HsPDE7A, Q13946; HsPDE8B, O95263; HsPDE9A7, Q86SI6;
HsPDE10A, Q6FHX1; HsPDE1A4, Q9HCR9; TbrPDEB1 (Trypanosoma brucei),
AAK33016; LmjPDEB1 (Leishmania major), AAR88146; LbrPDEB1 (Leishmania
braziliensis), A4H8B6; TcrPDEB1 (Trypanosoma cruzi), XP_820270; PfPDEa
(Plasmodium falciparum), ABS50256; PfPDEb, ABS50258; PfPDEg, ABS50259; PfPDEd,
ABS50260; GlPDE1 (Giardia lamblia), Q7QRM3; TvPDE1 (Trichomonas vaginalis),
A2E0E8; NgPDE1 (Naegleria gruberi), XP_002682684; TgPDE1 (Toxoplasma gondii),
B9PN68. Sequences were aligned using the MAFFT algorithm.
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Figure 3. Structure of LmjPDEB1
(A) Ribbon diagram of the LmjPDEB1 catalytic domain. (B) superposition of LmjPDEB1
(cyan) over human PDE4D (green). All structural figures were generated using the Ribbons
software package [93].
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Figure 4. 3-Isobutyl-1-methylxanthine binding
(A) Interaction of 3-isobutyl-1-methylxanthine with the LmjPDEB1 active site pocket. (B)
Superposition of LmjPDEB1 (green) over human PDE4D (gold and blue) interacting with 3-
isobutyl-1-methylxanthine.
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Figure 5. The putative parasite pocket (P-pocket)
(A) Superposition of the M-loop region of LmjPDEB1 (green) and of human PDE4D (blue).
The positioning of Rolipram is taken from the co-crystal of human PDE4D with rolipram.
(B) Surface presentation of the parasite pocket (P-pocket) in LmjPDEB1. (C) The sequence
alignment of the pocket among trypanosome, Leishmania and human PDEs. The red color
marks the identical amino acids in all phosphodiesterases. Two blue residues (Met-874 and
Gly-886 in LmjPDEB1) play a gatekeeper role to isolate the parasite pocket from the active
sites of human phosphodiesterase families [71].
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Figure 6. TbrPDEB1 and TbrPDEB2 are essential for trypanosome virulence
(A) Principle of tetracycline-inducible RNA interference (RNAi) [94]. 1: Genetic construct
containing a partial sequence (a few hundred base pairs) of the target mRNA, in opposite
orientations (arrows). In the absence of tetracycline, transcription is prevented by the
upstream binding of a tetracycline repressor; 2: In the presence of tetracycline, the repressor
dissociates and the sequence is transcribed; 3: The transcript folds into a partially double-
stranded hairpin structure; 4: This structure is recognized by the cellular RNAi machinery
and is degraded into 23 nucleotide fragments; 5: These fragments bind specifically to the
target mRNA to form partially double-stranded regions; 6: These are recognized by the
RNAi machinery, and the target mRNA is completely degraded. (B) Effect of in vivo RNAi
on the infection of mice. In animals that received tetracycline two days before the infection
in the drinking water, RNAi is induced and the mRNAs for TbrPDEB1 and TbrPDEB2 are
degraded. As a consequence, the parasites are killed, and no infection is produced (closed
circles). Control animals (no tetracycline) acquire fatal parasitemias of >108 trypanosomes/
ml blood within 3–4 days (open circles).
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Figure 7. Catechol ethers with high potency towards phosphodiesterase C of Trypanosoma cruzi
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Figure 8. Phosphodiesterase inhibitors with demonstrated activity against trypanosomatid
phosphodiesterases
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Figure 9. An inhibitor of LmjPDEB1
(A) A model targeting the P-pocket. (B) The compound 1-(3-(4-hydroxybutoxy)-4-
methoxyphenyl)-3-methylbutan-1-one binds to the active site of LmjPDEB1 and extends
into the P-pocket.
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